Qilu Pharmaceutical Co., Ltd.
204
39
43
30
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.5%
1 terminated/withdrawn out of 204 trials
96.8%
+10.3% vs industry average
30%
61 trials in Phase 3/4
0%
0 of 30 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (204)
SFRT+Sequential Hypofractionated/Conventional Fractionated RT+Iparomlimab and Tuvonralimab for Relapsed/Refractory Solid Tumors
Role: collaborator
QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms
Role: lead
Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCC
Role: collaborator
A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma
Role: collaborator
Efficacy and Safety of QLG1091 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes
Role: lead
QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Role: lead
Study of QLS1410 in the Treatment of Primary Aldosteronism.
Role: lead
Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer
Role: collaborator
A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer
Role: collaborator
A Study of QLH2405 in Healthy Participants and Participants With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
Role: lead
QLS1410 in Participants With Uncontrolled Hypertension
Role: lead
A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration
Role: lead
A Comparative Phase 1 Study to Evaluate the Pharmacokinetic and Safety of QL2106 vs Tremfye® in Healthy Subjects
Role: lead
QLS5212 for Participants With Advanced Solid Tumors
Role: lead
Study of QLS5308 in Patients With Advanced Solid Tumors
Role: lead
Safety and Efficacy Study of QL0911 to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients
Role: lead
QLS5132 Combination Therapy in Advanced Solid Tumors
Role: lead
QLC7401 in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)
Role: lead
QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated Low Density Lipoprotein Cholesterol (LDL-C)
Role: lead
QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed Dyslipidemia
Role: lead